首页 / 院系成果 / 成果详情页

The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism  期刊论文  

  • 编号:
    f2504606-3bef-4d9f-84e3-e1189dd930d6
  • 作者:
    Lu, Jianrao(路建饶)#*[1]Yi, Yang#[3]Xiong, Zhongxiang[1];Cheng, Xiufeng[1];Hu, Jing[1];Hang, Haiyan[1];Cheng, Jie[1];Peng, Wen(彭文)*[2]
  • 语种:
    英文
  • 期刊:
    BLOOD PURIFICATION ISSN:0253-5068 2016 年 42 卷 1 期 (3 - 8)
  • 收录:
  • 关键词:
  • 摘要:

    Objective: The study aimed to study the safety and efficacy of 1.25 mmol/l calcium dialysate on maintenance hemodialysis (MHD) in elderly patients who suffered from secondary hypoparathyroidism. Methods: Eighty-two elderly patients (ages >= 65) who had been in MHD with dialysate calcium at 1.5 mmol/l over 6 months and had 2 consecutive serum intact parathyroid hormone (iPTH) measurements at level below 100 pg/ml were selected and randomized into 2 groups: treatment group (41 patients, with dialysate calcium at 1.25 mmol/l) and control group (41 patients, still with dialysate calcium at 1.5 mmol/l). Both groups were studied for the duration of 12 months. The changes of serum iPTH, calcium, phosphorus, calcium and phosphorus product and other indicators as well as related adverse reactions were recorded at the following time points: before the study and 1, 3, 6 and 12 months into the study. In addition, the intimal media thickness (IMT) of carotid artery and abdominal aorta calcification score (AACS) were measured in the 0, 6 and 12 months during the study. Results: (1) In the treatment group, the levels of serum corrected calcium, phosphorus and calcium-phosphate product began to decline after 1 month and exhibited further decrease 3 months later. Serum iPTH level increased significantly after 1 month into the study and the trend continued. The above markers stabilized after month 6. Compared with pre-study markers, the changes of the above markers were significant after study (p < 0.05). (2) The aver-age IMT and AACS were evidently decreased during the 6 and 12 months of study in the treatment group. There was statistical significance (p < 0.05) when compared with the above indexes of the pre-study and the control group. (3) In the control group, there were no significant differences in above laboratory markers over the 12-month study period. (4) There was no significant difference in the adverse events observed between the 2 groups. Conclusion: Safety of low calcium dialysate (dialysate calcium 1.25 mmol/l) in elderly MHD patients with iPTH < 100 pg/ml is good, as well as improving carotid IMT, resistance index and AACS as indexes of vascular calcification in the small study group and warrants further investigation. (C) 2016 S. Karger AG, Basel

  • 推荐引用方式
    GB/T 7714:
    Lu Jian-rao,Yi Yang,Xiong Zhong-xiang, et al. The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism [J].BLOOD PURIFICATION,2016,42(1):3-8.
  • APA:
    Lu Jian-rao,Yi Yang,Xiong Zhong-xiang,Cheng Xiu-feng,&Peng Wen.(2016).The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism .BLOOD PURIFICATION,42(1):3-8.
  • MLA:
    Lu Jian-rao, et al. "The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism" .BLOOD PURIFICATION 42,1(2016):3-8.
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:42 下载次数:0
浏览次数:42
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部